Covid-19 vaccination campaign: 80% of residents
vaccinated
2020: growth in activity and Resilient profitability
- Revenue: €3,922 million (+4.9%)
- EBITDA: €926,5 million (-2.4%)
An expanding growth pipeline: +8,769 beds in 2020
- Pipeline of beds under construction of more
than 25,000 beds
- Network of more than 111,000 beds in 23
countries
Strong increase in real-estate portfolio valuation (+€789
million)
- Portfolio valuation at €6.8
billion
2021 Revenue growth target: at least +6%
Regulatory News:
The ORPEA Group (Paris:ORP), world leader in long-term care
(nursing homes, post-acute and rehabilitation and hospitals and
mental health facilities, and home care services) today announced
its consolidated results for the 2020 financial year1, ended on 31
December, which release has been approved by the Board of Directors
on 16 March 2021.
Management
of Covid-19: major improvement in the sanitary situation across all
Group facilities thanks to the success of the vaccination
campaign
The Covid-19 vaccination campaign, which is scheduled to be
completed across all countries in which the Group operates by the
beginning of April, coupled with the strong commitment of our
teams, has improved the sanitary situation within the ORPEA
network.
At 15 March 2021, 80% of residents and 44% of employees had been
vaccinated. Thanks to the success of these vaccinations, the number
of positive cases has decreased considerably and currently
represents less than 1% of the Group’s residents. More than 90% of
the Group’s nursing homes thus currently have no positive cases of
Covid-19.
Although the teams remain highly cautious and strict barrier
measures remain in place, the social life within each facility,
which is of utmost importance is gradually returning to normal:
meals at the restaurant, family visits, events and entertainment,
authorisations to leave the premises. ORPEA is providing customised
solutions in each region and each facility according to regulatory
requirements and the local public health context.
As has been the case each year for 20 years, ORPEA has carried
out an annual satisfaction survey among the residents of nursing
homes and their families worldwide: 50,000 questionnaires were
issued and the rate of response was 56%, a high level considering
the pandemic. Thanks to the unprecedented commitment of employees
during the past year of this public health crisis, the satisfaction
and recommendation rates have improved: reaching 92.5% (+0.2pt) and
95.1% (+1.2pts) respectively.
2020
results demonstrate the Group’s resilience in an unprecedented
context
Results for 2020 are presented in accordance with IFRS
standards, including IFRS 16.
In €m
(IFRS)
2020
2019
Change
Revenue
3,922.4
3,740.2
+4.9%
EBITDAR (EBITDA before rental
expenses)
963.0
982.5
-2.0%
EBITDA
926.5
949.4
-2.4%
Recurring operating profit
422.9
503.7
-16.0%
Net interest expense
-256.7
-215.0
+19.4%
Profit before tax
210.3
325.7
-35.4%
Net profit attributable to Group’s
shareholders
160.0
233.8
-31.6%
Revenue for 2020 was up +4.9% to €3,922.4 million, driven
by good external growth momentum in Ireland (TLC Group) and France
(Clinipsy, Sinoué). Moreover, the recovery in organic growth during
H2 offset the slight slowdown in growth seen during H1.
EBITDAR (EBITDA before rental expenses) recorded a
limited decline of 2% over the year as a whole, to €963 million
representing a margin of 24.6%, versus 26.3% in 2019, marking a
limited 170 bp decrease against a backdrop of a global
pandemic.
The gross cost of Covid-19 over 2020 was €259 million (loss of
business, additional costs relating to personal protective
equipment and staff bonuses), and the net cost €101 million, taking
into account compensation received. This compensation is recognised
as recurring profit, either mainly under other income for
compensation relating to loss of activity or as a reduction in
expenses for compensation for additional costs.
H2 2020 was characterised by a marked increase in profitability,
with an EBITDAR margin that improved by 150 bp to 25.3% versus
23.8% during H1, thanks to the upturn in business, mainly in
post-acute and rehabilitation hospitals and mental health
facilities. Central Europe and Eastern Europe enjoyed a strong
improvement in profitability during H2, whereas the Iberian
Peninsula and Latam continued to be affected by the scale of the
pandemic in Spain during H1.
EBITDA declined by a limited 2.4% to €926.5 million,
representing a margin of 23.6% (vs 23.1% during H1 2020).
Recurring operating profit stood at €422.9 million (-16%)
after depreciation, amortisation and charges to provisions of
€503.7 million (+13%) with the level of amortisation and
depreciation reflecting the growth of the real-estate portfolio
held by the Group.
Net non-recurring gains were €44.1 million compared with €37.0
million in 2019 (+19.2%).
The net interest expense reached €256.7 million (+19.4%), with
this increase mainly driven by a non-cash element relating to
provisions for interest rate hedging due to an environment of
sustained negative interest rates during 2020.
Against a backdrop of the global public health crisis that
impacted both levels of activity and operating expenses, net profit
attributable to Group’s shareholders reached €160 million (-31.6%).
Excluding IFRS 16, 2020 net profit stood at €174 million,
representing a decline of 29% compared to 2019.
Proposed
dividend distribution of €0.90 per share
In 2020, faced with an unprecedented situation, ORPEA was one of
the first groups to propose a dividend suspension in solidarity
with all stakeholders. This proposal was almost unanimously
approved (99%) by shareholders during the Annual General
Meeting.
Faced with the prospect of an improvement in the public health
situation, the Board of Directors, will propose, at the 24 June
2021 Annual General Meeting, that shareholders approve the
distribution of a dividend of €0.90 per share, entirely paid in
cash, with respect to the 2020 financial year. This amount implies
a pay-out ratio of 36%, allowing the Group to maintain its
investment capacity to improve and develop its network of
facilities.
Significant
growth in the real-estate portfolio to €6.8 billion
At 31 December 2020, the Group’s real-estate portfolio was
valued at €6,806 million2 and had a total surface area of more than
2.2 million sqm.
This significant improvement of €789 million (+13%) compared to
2019 was driven by:
– the revaluation (+€406 million) of all existing real estate
(as opposed to one third of the portfolio every three years) by
independent experts Cushman & Wakefield and JLL. This
assessment points to a capitalisation rate of 5.3% (vs 5.7% in
2019) that reflects changes to market conditions, but which
nonetheless remain conservative in terms of recent transactions of
assets falling within the same category;
– the continuation of developments associated with the ownership
of new buildings in prime locations, notably with the acquisition
of buildings in Ireland, Germany and the Netherlands (+€615
million);
– the disposal of facilities (-€232 million), in line with the
arbitrage strategy announced by the Group at the end of 2019.
As the public health crisis has demonstrated the resilience of
occupancy rates at healthcare facilities, the Group’s buildings
continue to attract an increasing number of international
real-estate investors, under conditions that remain very attractive
in terms of yield, the indexation of rental income and lease terms.
The Group has thus received commitments of more than €2 billion for
its 2021-2025 disposal programme.
ORPEA therefore now owns 47% of its facilities, which is in line
with the medium-term ownership rate objective of 50%.
Financial
structure strengthened further in 2020
In 2020, ORPEA continued to actively strengthen its financing
capacity, with new bank financing and non-banking transactions
(Schuldschein and Euro PP for almost €500 million), of which part
in long-term maturities (12 and 15 years), as well as a Private
Placement indexed to extra-financial impact criteria.
Net financial debt stood at €6,103 million3 at 31 December 2020,
compared with €5,958 million at 30 June 2020, a very modest
increase considering the level of investments, both in real estate
and operating assets.
The share of real estate debt reached 87%, compared with 85% at
31 December 2019. Debt ratios restated for IFRS 16, used by the
Group’s financial partners, remain well below their covenants, with
financial leverage restated for real estate assets at 3.4 (5.5
authorised) and stable restated gearing compared with 2019 at 1.6
(2.0 authorised). The Group therefore has good financial leeway to
execute its growth strategy.
Borrowing cost (including hedging costs) stood at 2.4%, a 30 bp
decrease compared to 2019. Net debt is still fully hedged against
the risk of an increase in interest rates.
Further
sustained growth for the network in 2020: +8,769 new beds in just
one year
At 31 December 2020, the ORPEA network extended across 23
countries, with 111,801 beds in 1,114 facilities, thanks to a
sustained pace of growth despite the Covid-19 pandemic.
Indeed, following an already steady increase of almost 8,000
beds in 2019, the Group continued its development policy by
increasing its network by 8,769 new beds (+8%) in 2020:
– +5,808 beds (i.e. 66% of the increase) through the creation of
facilities across all geographical regions, in particular in
France, Germany, Portugal and Mexico;
– +2,961 beds through external growth, via the acquisition of
groups (Sinoué and Clinipsy in France, TLC and Brindley in Ireland)
and independent facilities.
The growth pipeline, consisting exclusively of beds under
construction, posted growth in excess of 20% over 12 months to
reach a record level of 25,403 beds. This marked improvement, for
the third consecutive year, underlines the Group’s long-term growth
momentum, which remains unchanged despite the unprecedented context
of the public health crisis. This growth pipeline will allow the
Group to guarantee secure, sustainable and strong organic growth
for the next five years.
Number ofsites Beds in service Beds
underconstruction Number of beds Change in 12
months France Benelux
572
42,540
5,366
47,906
+3,838 France
372
32,673
3,543
36,216
+2,193 Netherlands
116
1,676
1,168
2,844
+583 Belgium
71
7230
268
7,498
79
Luxembourg
2
0
365
365
+0 Ireland
11
961
22
983
+983
Central Europe
261
22,148
5,828
27,976
+1,485 Germany
191
17,105
3,452
20,557
+974 Italy
30
1,977
1,518
3,495
+266 Switzerland
40
3,066
858
3,924
+245
Eastern Europe
142
11,154
4,101
15,255
+836 Austria
87
7,041
954
7,995
+180 Poland
23
1,190
1,696
2,886
+0 Czech Rep.
20
2,044
784
2,828
+103 Slovenia
9
551
467
1,018
+225 Latvia
1
202
202
+202 Croatia
1
126
126
+126 Russia
1
200
200
+0
Iberia and Latin America
137
10,416
9,723
20,139
+2,225 Spain
66
8,992
2,339
11,331
+254 Portugal
37
728
3,336
4,064
+956 Brazil
22
471
2,487
2,958
+206 Uruguay
3
100
209
309
-17
Colombia
4
0
641
641
+320 Mexico
5
125
711
836
+506
Other country
2
140
385
525
+385 China
2
140
385
525
+385
Total Group
1,114
86,398
25,403
111,801
8,769
Major
developments and investments in training
ORPEA’s employees are key to the Group’s success and a major
stakeholder within the CSR commitments of the Group. Achieving
sustainable growth requires the implementation of an innovative and
differentiating Human Resources strategy that meets three
fundamental challenges - recruitment, training and loyalty.
In terms of recruitment, ORPEA uses all the means available to
increase the visibility and attractiveness of its employer brand,
while diversifying its sources:
– strengthening its social media presence to better promote its
professions and careers,
– the digitalisation of HR processes, which has already achieved
tangible results with, for example, 5,000 unsolicited job
applications received in France and Germany,
– partnerships with non-profit organisations to attract new
profiles: “Nos quartiers ont du talent”, “Rev’elles ton Potentiel”,
“Viens Voir Mon Taf”,
– the development of Open Innovation through partnerships with
start-ups such as Hublo, a digital solution for the management of
replacement care staff which already has more than 9,000 candidates
registered in its database for ORPEA.
ORPEA has always considered training to be a cornerstone of its
HR development policy to enable all employees, regardless of their
position, to advance in their careers with no “glass ceiling”. The
Group has thus introduced major new initiatives in this area:
– the development of internal schools, for example in France
that now has two schools for carers capable of accepting 250
candidates each year;
– the acquisition of EMG Akademie, the leading nursing and care
school in Austria, associated with the construction of a campus
covering all Care-related courses, with a capacity of over 500
students;
– an acceleration in the Validation of Prior Experience (VAE)
programme: more than 600 nursing assistants will be able to become
carers in just two years;
– partnerships with prestigious universities to create
University Degrees specific to ORPEA’s fields of expertise: Degree
in Psychiatric Nursing, Degree in Hygiene, Degree in Troubled
Teens, etc.
The Group will continue to invest in its HR development strategy
to reinforce its attractiveness, attract and retain more talent,
and promote the personal and professional development of its
employees which is a key factor in terms of competitiveness for
ORPEA.
Strategy
and outlook
In 2021, the Group will remain extremely cautious in terms of
the public health situation and will continue to implement all of
its resources and know-how to protect its residents, patients and
employees and strengthen its relationship with and the well-being
of all its stakeholders. The Group has set the following
objectives:
– continue to grow in its five geographical areas across all
professions in long-term physical and mental health care, through
targeted acquisitions and new facility construction projects;
– open 4,055 new beds from the growth pipeline;
– revenue growth above 6% (> €4,155 million)
– real-estate disposals of €400-500 million, in line with its
strategy of owning around 50% of its property portfolio;
– roll out its CSR roadmap with 2023 objectives focused on its
five stakeholders: Residents, Patients & Families, Employees,
Partners, Environment, Society & Community.
Yves Le
Masne, Chief Executive Officer of ORPEA, commented:
“2020 was an unprecedented year in the scale and duration of the
global pandemic, but ORPEA, thanks to the commitment of its 68,000
employees, who I would like to once again thank for their
unwavering commitment, was able to demonstrate its ability to adapt
and resist. ORPEA thus posted revenue growth of close to 5%,
EBITDAR in slight decline of 2% compared to 2019 and net profit of
€160 million (€174 million restated for IFRS 16, -29%).
While remaining highly cautious to protect our residents and
patients, we are reasonably confident that the public health
situation will gradually return to normal, thanks in particular to
the success of the vaccination campaign.
In 2021, we will continue to broaden our CSR commitments,
notably by investing in the development, training and well-being of
our employees so that they are happy and proud to work, each day,
in a profession that has never been so useful and essential to our
society.
Lastly, the Group is confident in its ability to continue its
sustained global growth focused, as always, on value creation
through new acquisitions and the construction of new health
facilities."
About ORPEA (www.orpea-corp.com)
Founded in 1989, ORPEA is one of the major world leaders in
long-term care, with a network of 1,114 facilities comprising
111,801 beds (25,403 of which are under construction) across 23
countries, which are divided into five geographical regions:
- France Benelux: 572 facilities/47,906 beds (of which 5,366 are
under construction)
- Central Europe: 261 facilities/27,976 beds (of which 5,828 are
under construction)
- Eastern Europe: 142 facilities/15,255 beds (of which 4,101 are
under construction)
- Iberian Peninsula/Latin America: 137 facilities/20,139 beds
(of which 9,723 are under construction)
- Rest of the world: 2 facilities / 525 beds (of which 285 under
construction)
ORPEA is listed on Euronext Paris (ISIN code: FR0000184798) and
a constituent of the SBF 120, STOXX 600 Europe, MSCI Small Cap
Europe and CAC Mid 60 indices.
Next press release: Q1 2021 revenue 4 May
2021 after market close
Organic growth
Organic growth reflects the following
factors:
- The year-on-year change in the revenue of existing facilities
as a result of changes in their occupancy rates and per diem
rates
- The year-on-year change in the revenue of redeveloped
facilities or those where capacity has been increased in the
current or year-earlier period
- Revenue generated in the current period by facilities created
in the current or year-earlier period, and the change in revenue at
recently acquired facilities by comparison with the previous
equivalent period
EBITDAR
EBITDA before rents, including provisions
related to external charges and staff costs
EBITDA
Recurring operating profit before net
additions to depreciation and amortisation, including provisions
related to external charges and staff costs
Pre-tax profit on ordinary
activities
Recurring operating profit - Net financial
expense
Net debt
Non-current borrowings + current
borrowings - cash and short-term investments
Financial leverage restated for
real-estate assets
(Net debt - Real-estate debt)/(EBITDA -
(6% x Real-estate debt))
Restated gearing
Net debt/(Equity + Deferred taxes
available indefinitely on intangible assets)
Capitalisation rate
The real-estate capitalisation rate or the
rate of return is the ratio between the rental amount and the
building’s value
Consolidated income statement (Audit in progress)
In €m
2020
2019
2020
Restated IFRS 16
2019 Restated IFRS 16
Revenue
3,922.3
3,740.2
3,922.3
3,740.2
Purchases used and other external
expenses
-712.3
-685.6
-718.4
-685.6
Staff costs
-2,210.3
-1,978.1
-2,210.3
-1,978.1
Taxes other than on income
-135.5
-129.2
-135.5
-129.2
Depreciation, amortisation and charges to
provisions
-503.6
-445.7
-233.4
-198.5
Rents
-36.5
-33.1
-354.0
-331.4
Other recurring operating income and
expenses
98.8
35.1
98.8
35.1
Recurring operating profit
422.9
503.7
369.5
452.5
Other non-recurring operating income and
expenses
44.1
37
43.5
36.2
Net interest expense
-256.7
-215.0
-184.0
-147.9
Profit before tax
210.3
325.7
228.9
340.8
Income tax expense
-52.6
-98.6
-56.9
-101.6
Share in profit/(loss) of associates and
joint ventures
2.3
6.7
2.3
6.7
Net profit attributable to ORPEA’s
shareholders
160.0
233.8
174.3
245.9
Consolidated balance sheet (Audit in progress)
In €m
31-dec-20
31-dec-19
Non-current assets
14,398
12,440
Goodwill
1,489
1,299
Intangible assets
2,881
2,469
Property, plant and equipment and
properties under development
6,806
6,017
Right of use assets
2,817
2,334
Other non-current assets
405
321
Current assets
1,944
1,699
Cash and short-term investments
889
839
Assets held for sale
550
400
TOTAL ASSETS
16,892
14,539
Equity attributable to ORPEA’s
shareholders and deferred taxes available indefinitely
3,949
3,513
Equity attributable to ORPEA’s
shareholders
3,374
3,014
Deferred taxes available indefinitely on
operating intangible assets
576
499
Non-controlling interests
-5
-3
Non-current liabilities
9,998
8,849
Other deferred tax liabilities
625
529
Provisions for liabilities and charges
191
199
Non-current liabilities
6,462
5,859
Lease commitments
2,720
2,262
Current liabilities
2,399
1,780
o/w current financial liabilities (bridge
loans and real-estate porting)
530
515
Liabilities associated with assets held
for sale
550
400
TOTAL EQUITY AND LIABILITIES
16,892
14,539
Cash flows (Audit in progress)
In €m
2020
2019
Net cash from operating
activities
440
487
Investments in construction projects
-427
-375
Acquisitions of real-estate
-324
-343
Disposals of real-estate
232
16
Net operating investments and equity
investments
-488
-276
Net cash generated/(used) by investing
activities
-1,007
-978
Net cash generated/(used) by financing
activities
617
562
Change in cash over the period
50
71
Cash at end of period
889
839
1 The 2020 financial statements are currently being audited. 2
Excluding the impact of €490 million of real-estate assets held for
sale as of 31.12.20 3 Excluding €550 million and €400 million in
debt associated with assets held for sale at 31.12.2020 and 31.12.
2019 respectively.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210316005950/en/
Investor Relations ORPEA Steve Grobet EVP
Communication and Investor Relations s.grobet@orpea.net
Benoit Lesieur Investor relations b.lesieur@orpea.net
Investor Relations NewCap Dusan Oresansky Tel.:
+33 (0)1 44 71 94 94 orpea@newcap.eu
Media Relations Rebecca David Tél. : 06 04 74 83 69
rdavid@image7.fr
Charlotte Le Barbier Tel.: 06 78 37 27 60
clebarbier@image7.fr
Orpea (EU:ORP)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Orpea (EU:ORP)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024